Business Description
NeoGenomics Inc
NAICS : 541714
SIC : 8734
ISIN : US64049M2098
Description
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.66 | |||||
| Debt-to-EBITDA | -175.29 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.66 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.8 | |||||
| 3-Year FCF Growth Rate | 0.3 | |||||
| 3-Year Book Growth Rate | 6.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.24 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.16 | |||||
| 9-Day RSI | 22.9 | |||||
| 14-Day RSI | 28.97 | |||||
| 6-1 Month Momentum % | 5.93 | |||||
| 12-1 Month Momentum % | 26.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.01 | |||||
| Quick Ratio | 1.93 | |||||
| Cash Ratio | 1.34 | |||||
| Days Inventory | 23.64 | |||||
| Days Sales Outstanding | 78.57 | |||||
| Days Payable | 18.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.4 | |||||
| Shareholder Yield % | -0.18 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.64 | |||||
| Operating Margin % | -14.01 | |||||
| Net Margin % | -12.5 | |||||
| FCF Margin % | -4.74 | |||||
| ROE % | -8.38 | |||||
| ROA % | -4.71 | |||||
| ROIC % | -6.62 | |||||
| 3-Year ROIIC % | -15.95 | |||||
| ROC (Joel Greenblatt) % | -27.05 | |||||
| ROCE % | -4.96 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 82.49 | |||||
| PS Ratio | 2.76 | |||||
| PB Ratio | 1.92 | |||||
| Price-to-Tangible-Book | 46.54 | |||||
| Price-to-Operating-Cash-Flow | 6890 | |||||
| EV-to-EBIT | -25.45 | |||||
| EV-to-EBITDA | -561.52 | |||||
| EV-to-Revenue | 3.09 | |||||
| EV-to-Forward-Revenue | 2.49 | |||||
| EV-to-FCF | -66.76 | |||||
| Price-to-Projected-FCF | 5.28 | |||||
| Price-to-Median-PS-Value | 0.69 | |||||
| Earnings Yield (Greenblatt) % | -3.93 | |||||
| FCF Yield % | -1.72 | |||||
| Forward Rate of Return (Yacktman) % | -8.76 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers